Thursday, March 08, 2007

Makers of Potential Mesothelioma Treatment Seeks Orphan Drug Status (Part 2)

Back in December we posted news about Biopharmaceutical company Alfacell Corp. asking the Food and Drug Administration to grant its lead drug candidate, Onconase, orphan drug status in the post - Makers of Potential Mesothelioma Treatment Seeks Orphan Drug Status (Part 1)

On January 30th, the Food and Drug Administration granted U.S. orphan drug designation for ONCONASE(R) for treatment of malignant mesothelioma. The generic name for Onconase(R) is Ranprinase.

Use the following links for orphan products:
For more information on malignant mesothelioma and Onconase, please visit:

No comments: